Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study

Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study

Background and aim: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucose-lowering drugs that increase urinary glucose excretion have been shown to reduce CV events in patients with type 2 diabetes (T2D). Furthermore, several studies have demonstrated that treatment with SGLT2 inhibitors affect...

Full description

Bibliographic Details
Main Authors: Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Julia Möllmann, Stephanie Wied, Mathias Hohl, Nikolaus Marx, Michael Lehrke
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Bone Reports
Subjects:
Type 2 diabetes
SGLT2 inhibitors
Empagliflozin
Serum phosphate
FGF23
PTH
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187222000109

Internet

http://www.sciencedirect.com/science/article/pii/S2352187222000109

Similar Items